Travere Therapeutics (TVTX)
(Delayed Data from NSDQ)
$17.24 USD
+0.56 (3.36%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $18.00 +0.76 (4.41%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TVTX 17.24 +0.56(3.36%)
Will TVTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TVTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TVTX
Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
TVTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics
Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates
Other News for TVTX
Travere Therapeutics, Inc. 2025 Q2 - Results - Earnings Call Presentation
Travere Therapeutics Non-GAAP EPS of $0.13 beats by $0.14, revenue of $114.45M beats by $14.28M
Travere Therapeutics Inc Reports Q2 2025 Earnings: EPS Loss of $0. ...
Earnings Scheduled For August 6, 2025
Travere Therapeutics reports Q2 EPS (14c), consensus (1c)